Clinical and Molecular Features of Our Pompe Patients: Single-Center Experience
- 1 March 2020
- journal article
- research article
- Published by Galenos Yayinevi in Medical Journal of Bakırkoy
- Vol. 16 (1), 49-55
- https://doi.org/10.5222/BMJ.2020.91855
Abstract
Introduction: Pompe disease (PD), glycogen storage disease Type II (GSD II), is an autosomal recessive inherited lysosomal storage disease caused by pathogenic variants in the GAA gene that encodes lysosomal acid alpha-glucosidadase (GAA) enzyme. The incidence of the disease varies from country to country. PD is mainly presents as two groups of phenotypes as infantile-onset Pompe disease (IOPD) and late-onset Pompe disease. Objective: The aim of this study is to discuss the molecular and clinical characteristics of infantile-onset Pompe disease (IOPD) and late-onset pompe disease (LOPD) followed-up in our center. Method: A total of 10 patients diagnosed with IOPD and 4 patients diagnosed with LOPD in Izmir Dr. Behcet Uz Pediatric Health and Diseases and Surgery Training and Research Hospital Pediatric Metabolism Unit between 06.01.2015 and 06.01. 2019 were included in the study. The patients' demographic characteristics, clinical findings at the time of diagnosis and during the folllow-up period, biochemical findings, muscle biopsy data, results of enzymatic analyses and molecular-genetic characteristics were recorded retrospectively. Results: A total of 10 patients were included in the study. 7 patients were diagnosed with IOPD and 3 patients with LOPD. The median follow-up period of all patients was 26 months (range: 6-42 months). The c.896 C> T (8/32, 25%) is detected as the most common variant. 1237G>T (p.Asp413Tyr), c.2019 C>A (p.Asn673Lys), c.418A>T (p.Asn140Tyr) variants were detected for the first time. Conclusion: Pompe disease is one of the most important congenital metabolic diseases in which early diagnosis and treatment are of great importance. Despite the significant improvement in disease prognosis with the introduction of enzyme replacement therapy, there are still patients with poor prognosis despite early diagnosis. Phenotype-genotype studies are crucial in this respect.This publication has 19 references indexed in Scilit:
- Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe diseaseJournal of Inherited Metabolic Disease, 2014
- How to describe the clinical spectrum in Pompe disease?American Journal of Medical Genetics Part A, 2013
- Lysosomal storage disorder 4+1 multiplex assay for newborn screening using tandem mass spectrometry: Application to a small-scale population study for five lysosomal storage disordersClinica Chimica Acta; International Journal of Clinical Chemistry, 2012
- The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe diseaseGenetics in Medicine, 2011
- Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe diseaseHuman Mutation, 2008
- Glycogen storage disease type II in Spanish patients: High frequency of c.1076-1G>C mutationMolecular Genetics and Metabolism, 2007
- Sibling phenotype concordance in classical infantile Pompe diseaseAmerican Journal of Medical Genetics Part A, 2007
- Mutation profile of theGAA gene in 40 Italian patients with late onset glycogen storage disease type IIHuman Mutation, 2006
- Pompe disease diagnosis and management guidelineGenetics in Medicine, 2006
- Respiratory insufficiency and limb muscle weakness in adults with Pompe's diseaseEuropean Respiratory Journal, 2005